| TGTX Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the TGTX shares outstanding history going back to 4/30/2012:
Also see: TGTX Market Cap History TGTX YTD Return |
TGTX Shares Outstanding History — TG Therapeutics Share Count Over Time
As of 5/1/2026 TG Therapeutics has 153.08 million TGTX shares outstanding. Investors often track the TGTX shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows TGTX share count trends over time, with 60 historical shares outstanding datapoints presented, dating back to 4/30/2012.
| TGTX Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TGTX Historical Shares Outstanding: +27.55% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TGTX Stock Price Chart |
| About TG Therapeutics Inc |
| TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. Co. is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. We show 60 historical shares outstanding datapoints in our coverage of TGTX's shares outstanding history. Understanding the changing numbers of TGTX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like TGTX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching TGTX by allowing them to research TGTX shares outstanding history as well as any other stock in our coverage universe. |
| TGTX Current Stock Quote |
Quotes delayed 20 minutes  Free TGTX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| TGTX Share Performance |
| Shares Outstanding Peers |
| TG Therapeutics (TGTX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
THAR Shares Outstanding History THC Shares Outstanding History THMO Shares Outstanding History THOR Shares Outstanding History THRD Shares Outstanding History THRN Shares Outstanding History THRX Shares Outstanding History TIL Shares Outstanding History TIVC Shares Outstanding History TKNO Shares Outstanding History More Healthcare companies » |
TGTX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
